Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : The Microcap Kitchen: Stocks 5¢ to $5 -- Ignore unavailable to you. Want to Upgrade?

To: Ted M who wrote (99854)	9/20/2010 1:51:04 PM
From: Ted M	Read Replies (2) \| Respond to of 120405

IVOB short term potential: Found in this article are a number of things that might be around the corner. thecleverbull.com 1. Clinical trial results "INVO Bioscience is awaiting the final result of another Clinical Trial Performed at CECOLFES (Columbia), INVO Bioscience has performed 90 INVO cycles and numbers will be out very soon around October. We have been told by the management that it will be a very high rate number, something to be considered has a huge news. The general consensus being that the results are highly positive for the InvoCell device around the world." 2. Canada promotion "INVO Bioscience is now moving to strengthen its position in North America. In Canada, INVO Bioscience has signed a distribution agreement with Invaron Pharmaceuticals. The InvoCell device has the CE Mark so there is no need to conduct clinical studies in Canada, however the device needs to be introduced and presented to IVF clinics across the country, the process has already started and major IVF centres have been approached already to use the InvoCell device. We have heard that articles about the InvoCell should be released in different major Canadian newspapers, getting some credibility and publicity for InvoCell among infertile couples throughout the country." 3. US clinical trial financing "INVO Bioscience is also focusing on starting the US clinical trial, management is in discussions with potential development and commercialization partners in the U.S. and Canada. The potential exists that something gets done to provide additional funding for expansion of the marketing and promotional effort behind Invocell in 2011...Regarding the financing, INVO Bioscience is now focusing on finding a partner by in-licensing. We are hearing some very loud and credible chatter that an in-licensing deal might happen with a big pharma in Canada or USA. Additionally, INVO Bioscience qualified for a U.S. federal research grant between $500k and $1 million to start to fund the U.S. regulatory FDA trial for INVOcell. Management has already applied for these funds and expects to hear back by the end of September." Their conclusion: "The actual market cap of $2M is ridiculous considering that INVO Bioscience is becoming a strong and recognized company in the infertility field. With a unique device product already CE mark and an international distribution network in place, it would worth already at the very least 10 times the actual market cap! The Zack’s analyst has an outperform recommendation with a target price of $0.25. We believe that major news are going to be released, we are awaiting for the clinical trial result in Columbia and have been told that it might be surprising and big, also a positive answer from the Federal R&D Tax Credit would be a very big news for the company and investors. The work already accomplished by the company is amazing and while it is taking more time than anticipated to increase revenue and resulting income, 2011 should improve dramatically for INVO Bioscience. With an estimated 150 million infertile couples worldwide, at the current market value of only $2M, we believe that this is dramatically underappreciated by Wall Street, recent developments and coming news should easily push up the price above the $0.20 range again."